Kaleido Biosciences logo
Kaleido Biosciences KLDO

Annual report 2021
added 12-23-2023

report update icon

Kaleido Biosciences Income Statement 2011-2026 | KLDO

Annual Income Statement Kaleido Biosciences

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

73.7 M 538 M 221 M - - - - - - - -

Shares

41.9 M 36 M 25.7 M - - - - - - - -

Historical Prices

1.76 14.9 8.58 - - - - - - - -

Net Income

-90.3 M -81.6 M -86.3 M -61.7 M -27.6 M -9.68 M - - - - -

Revenue

1.1 M 975 K - - - - - - - - -

Gross Profit

- 975 K - - - - - - - - -

Operating Income

-87.7 M -78.9 M -86.7 M -60.7 M - - - - - - -

Interest Expense

2.84 M 2.8 M 977 K 1 M - - - - - - -

EBITDA

-85.3 M -77.1 M -85.4 M -59.9 M -26.7 M -9.34 M - - - - -

Operating Expenses

88.8 M 79.8 M 86.7 M - - - - - - - -

General and Administrative Expenses

21 M 23.9 M 22.4 M 18.6 M 6.04 M 1.57 M - - - - -

All numbers in USD currency

Quarterly Income Statement Kaleido Biosciences

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- - - - 42.6 M 42.6 M 42.5 M 39.7 M 36 M 35.6 M 31.9 M 30.3 M 30.1 M 29.9 M 29.7 M 13 M 5.79 M 5.15 M 4.81 M 4.74 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

- - - - - -23.1 M -23.9 M -23 M - -23.1 M -18.9 M -19.6 M - -22 M -24.6 M -20.2 M - -17.4 M -12.3 M -10.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- - - - - 104 K 211 K 297 K - 482 K 250 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - - - - -22.4 M -23.2 M -22.3 M - -22.4 M -18.1 M -19.1 M - -22.1 M -25 M -20.6 M - -17.3 M -12.4 M -10.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - - - - 709 K 705 K 709 K - 713 K 683 K 688 K - 258 K 260 K 258 K - 243 K 253 K 249 K - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - - - -21.8 M -22.6 M -21.8 M - -21.9 M -17.8 M -18.7 M - -21.8 M -24.6 M -20.3 M - -17.1 M -12.2 M -10.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- - - - - 22.5 M 23.4 M 22.6 M - 22.9 M 18.4 M 19.1 M - 22.1 M 25 M 20.6 M - 17.3 M 12.4 M 10.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

- - - - - 5.11 M 5.78 M 5.46 M - 7.2 M 5.56 M 5.92 M - 5.93 M 6.18 M 5.43 M - 7.14 M 3.21 M 2.67 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Kaleido Biosciences (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 3.78 - $ 105 M schweizSchweiz
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.35 -2.17 % $ 347 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 3.5 -21.7 % $ 236 B britainBritain
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
$ 1.58 -4.82 % $ 94.9 M usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 8.36 4.89 % $ 82.6 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 330.71 3.72 % $ 43.3 B usaUSA
Altimmune Altimmune
ALT
$ 3.47 3.89 % $ 306 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 1.98 0.25 % $ 106 M usaUSA
Amgen Amgen
AMGN
$ 346.45 -0.43 % $ 186 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 12.37 -0.92 % $ 3.88 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Anika Therapeutics Anika Therapeutics
ANIK
$ 15.0 1.32 % $ 220 M usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 76.34 2.87 % $ 1.47 B usaUSA
Annexon Annexon
ANNX
$ 5.64 2.45 % $ 875 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.92 -1.11 % $ 5.02 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Aprea Therapeutics Aprea Therapeutics
APRE
$ 0.73 2.63 % $ 4.77 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.15 0.48 % $ 444 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.43 4.98 % $ 231 M israelIsrael
Ardelyx Ardelyx
ARDX
$ 6.08 2.27 % $ 1.47 B usaUSA
argenx SE argenx SE
ARGX
$ 752.05 0.75 % $ 25 B niderlandNiderland
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.93 1.27 % $ 3.04 B usaUSA
Arvinas Arvinas
ARVN
$ 11.11 2.4 % $ 788 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 61.57 0.88 % $ 8.24 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 30.01 3.43 % $ 336 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
$ 1.14 16.28 % $ 35.6 M usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
$ 5.21 -2.89 % $ 44.9 M usaUSA
Atara Biotherapeutics Atara Biotherapeutics
ATRA
$ 5.03 0.7 % $ 63.1 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 16.04 2.75 % $ 2.16 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.42 0.35 % $ 378 M britainBritain
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA